Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at SunTrust Banks lifted their FY2020 earnings per share estimates for shares of Regeneron Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst Y. Suneja now anticipates that the biopharmaceutical company will post earnings of $19.07 per share for the year, up from their prior estimate of $18.97. SunTrust Banks has a “Hold” rating and a $435.00 price objective on the stock.
A number of other brokerages have also recently commented on REGN. Bank of America Corporation restated a “buy” rating and issued a $593.00 price target (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets reaffirmed a “market perform” rating and issued a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Barclays PLC reaffirmed an “equal weight” rating and issued a $450.00 price objective (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a research note on Saturday, July 22nd. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $575.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 7th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $481.49.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $8.52 on Monday, reaching $385.10. The company’s stock had a trading volume of 532,547 shares, compared to its average volume of 902,722. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The stock has a market capitalization of $43,346.87, a PE ratio of 35.03, a price-to-earnings-growth ratio of 1.56 and a beta of 1.56. Regeneron Pharmaceuticals has a fifty-two week low of $340.09 and a fifty-two week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.13 earnings per share.
A number of hedge funds and other institutional investors have recently made changes to their positions in REGN. AQR Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 201.4% during the 1st quarter. AQR Capital Management LLC now owns 8,805 shares of the biopharmaceutical company’s stock valued at $3,412,000 after acquiring an additional 5,884 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $233,000. Fisher Asset Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 75.1% in the 2nd quarter. Fisher Asset Management LLC now owns 1,411 shares of the biopharmaceutical company’s stock worth $693,000 after purchasing an additional 605 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $642,000. Finally, Wendell David Associates Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $204,000. 67.80% of the stock is currently owned by institutional investors and hedge funds.
In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 468 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $476.45, for a total transaction of $222,978.60. Following the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at approximately $4,335,218.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the sale, the director now directly owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. Insiders have sold a total of 88,942 shares of company stock worth $42,064,076 over the last 90 days. 10.80% of the stock is currently owned by company insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.